Showing results (1611-1620 of 1,659) with videos related to

Sort By:
Pageof 166
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Transplantation and Cellular Therapy|June 18, 2026
Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary OutcomesNathan H Parker, Jongphil Kim, Morgan Bean, et al.
Blood|December 9, 2024
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomesCiara L Freeman, Jerald Noble, Meghan Menges, et al.
Environmental Research|December 3, 2014
The Danish contribution to the European DEMOCOPHES project: A description of cadmium, cotinine and mercury levels in Danish mother-child pairs and the perspectives of supplementary sampling and measurementsThit A Mørck, Flemming Nielsen, Jeanette K S Nielsen, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Bone Marrow Transplantation|May 11, 2026
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myelomaLaura B Oswald, Xiaoyin Li, Lisa M Gudenkauf, et al.
Diabetologia|June 10, 2021
Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY studyRoderick C Slieker, Louise A Donnelly, Hugo Fitipaldi, et al.
Blood|October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Journal for Immunotherapy of Cancer|January 13, 2023
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammationViktoria Marquardt, Johanna Theruvath, David Pauck, et al.
Nature Communications|July 2, 2025
The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trialJohanne K Hansen, Mads Israelsen, Suguru Nishijima, et al.
Pageof 166